Lopinavir is an HIV protease inhibitor used in a fixed-dose combination with Ritonavir. It is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir, under the trade names Kaletra and Aluvia. It was first approved by the FDA on 15 September 2000.
Chemical Formula: C37H48N4O5
Exact Mass: 628.36247
Molecular Weight: 628.8
Elemental Analysis: C, 70.67; H, 7.69; N, 8.91; O, 12.72
Chemical Name: (2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide
InChi Code: InChI=1S/C37H48N4O5/c1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t30-,31-,32-,34-/m0/s1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
Aline F, Aurélie R, Matthias C, Olivier B, Thierry B, Paule SM, Chantal C. Comparison of population pharmacokinetics based on steady-state assumption versus electronically monitored adherence to lopinavir, atazanavir, efavirenz, and etravirine: A retrospective study. Ther Drug Monit. 2016 Mar 1. [Epub ahead of print] PubMed PMID: 26937748.
Pandie M, Wiesner L, McIlleron H, Hughes J, Siwendu S, Conradie F, Variava E, Maartens G. Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB.J Antimicrob Chemother. 2016 Apr;71(4):1037-40.doi: 10.1093/jac/dkv447. Epub 2016 Jan 7. PubMed PMID: 26747099.
Raposo LM, Arruda MB, de Brindeiro RM, Nobre FF. Lopinavir Resistance Classification with Imbalanced Data Using Probabilistic Neural Networks. J Med Syst. 2016 Mar;40(3):69. doi: 10.1007/s10916-015-0428-7. Epub 2016 Jan 6. PubMed PMID: 26733278.
Srinivas NR. Prediction of area under the concentration-time curve for lopinavir from peak or trough lopinavir concentrations in patients receiving lopinavir-ritonavir therapy. Am J Health Syst Pharm. 2016 Mar 15;73(6):376-85. doi: 10.2146/ajhp150417. PubMed PMID: 26953282.
Patel G, Shelat P, Lalwani A. Statistical modeling, optimization and characterization of solid self-nanoemulsifying drug delivery system of lopinavir using design of experiment. Drug Deliv. 2016 Feb 16:1-16. [Epub ahead of print] PubMed PMID: 26882014.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.